Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
link
Tags
drugs
11
×
life sciences
national blog main
clinical trials
boston blog main
boston top stories
biotech
fda
national top stories
new york blog main
new york top stories
amgen
boston
cancer
indiana blog main
indiana top stories
san diego blog main
san diego top stories
san francisco blog main
svb leerink
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
detroit blog main
detroit top stories
eli lilly
marc goodman
migraine
national
raleigh-durham blog main
raleigh-durham top stories
rna interference
san francisco top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
What
drug
11
×
new
11
×
fda
medicine
approved
data
medicines
alnylam
approval
cancer
class
drugs
make
migraine
oks
pharmaceuticals
potentially
research
rna
second
won
actually
additional
advance
agency
aggressive
aldeyra
announced
arguments
based
big
biologic
biology
brexanolone
called
cannabis
cells
cholesterol
cleared
closer
Language
unset
Current search:
drug
×
new
×
drugs
×
@bgr.com
2 years ago
New drug recall issued: Stop taking these cold & flu medicines immediately
@bgr.com
3 years ago
A drug for diarrhea can kill aggressive cancer cells
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs
@WIRED
7 years ago
The DEA just opened a path for more research into marijuana—and that could make it easier to reschedule the drug.